-
Orders and sales growth, Chuanyi's 2021 performance is expected to increase significantly
Time of Update: 2022-03-06
34%; net profit attributable to shareholders of listed companies is expected to be The net profit attributable to deducting non-recurring gains and losses is expected to be 368 million yuan, an increase of 28.
-
Qilu Pharmaceutical Duloxetine Hydrochloride Enteric-coated Capsules Will Pass Consistency Evaluation
Time of Update: 2021-05-09
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with duloxetine hydrochloride enteric-coated capsules for imitation of category 4 applications.
0 Chinese Drug Evaluation DatabaseAt present, 12 companies have submitted supplementary applications for the consistency evaluation of duloxetine hydrochloride enteric-coated capsules or submitted for production under the new classification.
-
Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too
Time of Update: 2021-04-27
0 Chinese Drug Evaluation DatabaseIn recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
-
Dow Chemical's 2014 earnings report profit does not rise or fall
Time of Update: 2021-03-14
The plastics business accounted for two-thirds of full-year revenue, while the polyurethane business posted record fourth-quarter sales and double-digit growth.
Sales of its high-performance materials and chemicals business, which includes polyurethanes and epoxy resins, rose 2 percent to $15.1 billion.
-
Could China's new regulations on inventors affect the cro industry
Time of Update: 2014-09-04
Source: pharmasia news 2014-09-04 Shanghai - SIPO is drafting a new regulation on "service invention", which aims to encourage Chinese enterprises and researchers to increase investment in innovation
